Asociatia Romana pentru Studiul Ficatului organizeaza a XXII-a editie a Congresului National de Hepatologie, in perioada 27-29 septembrie, la Bucuresti, in colaborare cu: Institutul Clinic Fundeni, Asociatia Franceza pentru Studiul Ficatului, Societatea Romana de Gastroenterologie si Hepatologie, Universitatea de Medicina si Farmacie "Carol Davila" Bucuresti si Fundatia Academician "Marin Voiculescu.
Tema editiei actuale a Congresului este:"Hepatologie 2012 - Antivirale Noi, Orizonturi Noi"
In paralel, se vor organiza: Al doilea
Congres Romano-Francez de Hepatologie si Al treilea
Curs Balcanic de Hepatologie.
Inscrierea la Al XXII-lea Congres National de Hepatologie, AL Doilea Congres Romano-Francez de Hepatologie si Al Treilea Curs Balcanic de Hepatologie:
Taxele:
Cotizatia ARSF pe anul 2012: 50 RON
Taxa de participare si cotizatia ARSF vor fi achitate catre:
Asociatia Romana pentru Studiul Ficatului
IBAN: RO25 RNCB 0073 0499 7808 0001
BCR sucursala
sector 2, Bucuresti.
CIF: 9376140
Va rugam sa trimiteti dovada achitarii taxei de participare pe email sau fax:
E-mail:
contact@arsf.ro;
laurentiumicu2000@yahoo.com
Fax: 021.3119190
Taxa de participare include participarea la lucrari, certificatul de participare cu credite EMC, mapa cu materialele Congresului, volumul de rezumate, pauzele de cafea.
Pentru inscrieri accesati
site-ul organizatorilor.
Programul Congresului National de Hepatologie
Thursday, 27 September 2012
08.30-09.00: Opening ceremony
09.00-10.30: Challenges of HBV infection in 2012
Chairmen: P. Marcellin, M. Voiculescu
1. HBV treatment in 2012. T. Asselah
2. Long term results of HBV treatment. M. Voiculescu
3. Management of HBV infection in special groups of patients. L.Micu
4. Future of HBV infection treatment. P.Marcellin
Discussions
10.30-11.30: Symposium (BMS) - 1
11.30-12.00: Coffee break
12.00-13.30: Advances in HCV infection treatment
Chairmen: V Ratziu, T.Asselah
1. Triple therapy in HCV infection: the Romanian experience. - Laura Iliescu
2. Triple therapy in HCV infection: the French experience. - V. Ratziu
3. Management of side effects in protease inhibitor based therapy - L. Serfaty
4. Management of HCV infection in kidney transplant recipients - Ileana Constantinescu
Discussions
13.30-14.30: Lunch break
14.30-15.30: Symposium (BMS) - 2
15.30-18.00: Current therapies in HCC
Chairmen: L. De Carlis , I Popescu, D. Forti
a. Non-surgical
1. Who should treat and how to treat HCC: the 2012 EASL Guidelines - Monica Acalovschi
2. Locoregional therapies in HCC: Italian experience: A. Rampoldi
3. Locoregional therapies in HCC: French experience: V. Vilgrain
4. New target therapies for HCC: Mariana Mihaila
b. Surgical
5. Surgical therapy in HCC. I.Popescu
6. Liver transplant for HCC: L. De Carlis
7. Liver transplantation for HBV infection. D.Samuel
18.00-19.00: Symposium MSD
Friday, September 28, 2012
08.30-10.30: NASH
Chairmen: L. Serfaty, M. Acalovschi
1. What part does NASH play in today's clinical Hepatology ?: D. Larrey
2. Primary nonalcoholic fatty liver disease. Natural history. Prognosis- D. Olteanu
3. When does the hepatologist need to treat insulin resistance?- M. R. Gomez
4. The role of Breath-test in the diagnosis of NASH- C. Fierbinteanu
10.30 - 11.00: Symposium Merz
11.00 - 12.00: Symposium (Roche)
Pauza: 12.00 - 12.30
Third Balkan Hepatology Course XXII-nd National Congress of Hepatology
Friday, September 28, 2012
12.30-12.45 - OPEN CEREMONY
12.45-14.45 - "HBV infection- how to monitor the treatment and how to manage side effects and to prevent resistance"
- Vlad Ratziu (France) - "Response guided treatment in chronic hepatitis B"
- Patrick Marcellin (France) -"The future of therapy of HBV Chronic infection"
- Zahari Krastev (Bulgary) -"How to postpone the treatment with NUCs in chronic hepatitis B"
- Emanuel Mannesis (Greece) -"Is HbsAg useful in monitoring therapy for HBV infection?"
- Stephanos Hadziyannis (Greece) -"Is there still a place for IFN therapy in HBV infection?"
14.45-16.45 - "HCV infection- how to monitor and to manage side effects of DAA treatment"
- Antonio Craxi (Italy) -"Triple therapy with first-generation protease inhibitors in patients with cirrhosis- issues and management"
- Rafael Esteban (Spain) -"It is possible to predict therapeutical response: reality or utopia?"
- Christoph Sarrazin (Germany)-"Resistance to protease inhibitors: the magnitude of the problem and how to prevent it?"
- Anca Trifan -"Management of adverse events of Boceprevir and Telaprevir in HCV chronic infection"
- Peter Ferenci (Austria)-"The future of triple therapy in HCV infection: is IFN still necessary?"
18.00: Special Ceremony
Saturday, September 29, 2012
08.30-11.00 - "Liver cirrhosis and its complications" - Chairmen: A.Sanyal, P.Ferenci
- Arun Sanyal (USA) -"Keeping the patient with end-stage liver disease alive"
- Peter Ferenci (Austria) -"Current therapy of portal encephalopathy"
- Oliviu Pascu (Romania) -"Subclinical portal encephalopathy"
- Carol Stanciu (Romania) -"Esophageal variceal bleeding- current strategies"
- Eugenia Mindrut (Romania) -"Pathogenesis of hepato-renal syndrome"
- Camelia Achim (Romania) -"Current therapies in hepato-renal syndrome"
11.00-11.30 - Conferinta Magistrala - Prof. Alexandru Oproiu
11.30-12.00 - Symposion Afa Wassermann
12.00-13.30 - "NASH ": Chairmen: M.Neuman, G.Sebastiani
- Manuela Neuman (Canada) - Biomarkers in NASH
- Giada Sebastiani (Canada) - Non-invasive assessment of liver fibrosis in NASH
- Mona Munteanu (France) - Non-invasive biomarkers & liver and cardiovascular prognosis in NAFLD at-risk patients. How to associate biomarkers to better diagnose cirrhosis?
- Vlad Ratziu (France) - conference title will be announced
- Raluca Pais (France) - NASH: from clinical practice guidelines to real life settings
13.30-14.30 - Lunch break
14.30-15.30 - Symposion
15.30-17.30 - "Hepatitis Delta virus" - Chairmen: C. Yurdaydin, C. Trepo
- Christian Trepo (France) - Chronic Delta hepatitis : historical perspective and unresolved issues
- Azra Husic Selimovici (Bosnia and Herzegovina) - Epidemiological aspects,detection and prophylaxis of HDV
- Mithat Bozdayi (Turkey) - Chronic Delta hepatitis : historical perspective and unresolved issues
- Cihan Yurdaydin (Turkey) - Treatment of chronic delta hepatitis
Postere:
In cadrul congresului se va organiza o sesiune de postere evaluate de o comisie de experti.Posterele vor fi expuse de joi 27 septembrie pana sambata 29 septembrie. Informatiile privind dimensiunile posterelor, orele de montare si de demontare vor fi comunicate autorilor impreuna cu notificarea de acceptare.
Posterele vor fi evaluate de o comisie de experti, iar cele mai valoroase 3 postere vor fi premiate.
Participantii vor beneficia de asemenea de:
- 3 premii oferite participantilor: doua pentru cel mai bun poster si unul pentru cea mai buna comunicare libera
- Cel mai bun poster va fi premiat si prezentat in sesiunea de comunicari din ultima zi
- Cel mai bun material va fi publicat in Romanian Journal of Hepatology
- Emiterea de certificate EMC avand cel mai ridicat punctaj EMC din acest an acordat de Colegiul Medicilor
- Acordarea unei inscrieri si a unui bilet pentru un congres international in zona europeana
- Echipamente de birotica (o tableta, un telefon si un reportofon) si echipamente medicale (1 puls oximetru si un spirometru portative Vitalograf)
Va rugam sa trimiteti rezumatele posterelor, maxim o pagina A4, Times New Roman 11p, pe adresa contact@arsf.ro.
Participantii vor beneficia de asemenea de:
- Sesiune de postere special organizata pentru participanti
- 3 premii oferite participantilor: doua pentru cel mai bun poster si unul pentru cea mai buna comunicare libera
- Cel mai bun poster va fi premiat si prezentat in sesiunea de comunicari din ultima zi
- Cel mai bun material va fi publicat in Romanian Journal of Hepatology
Pentru informatii privind lectorii invitatii, precum si referitoare la presedintii manifestarii stiintifice, accesati posterul oficial al evenimentului.
